tri-tert-butyl 2,2',2''-(10-(2-(allyloxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate | 1412494-55-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tri-tert-butyl 2,2',2''-(10-(2-(allyloxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
• CAS: 1412494-55-3
• 化学式: C₃₁H₅₆N₄O₈
• 分子量: 612.808
• InChiKey: NGHWCALXPBUCON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.96
• 重原子数：
  43.0
• 可旋转键数：
  10.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  118.16
• 氢给体数：
  0.0
• 氢受体数：
  12.0

反应信息

• 作为反应物：
  描述：

  tri-tert-butyl 2,2',2''-(10-(2-(allyloxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 在 N-甲基吗啉 、 四(三苯基膦)钯 、 三异丙基硅烷 、 水 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸
  参考文献：
  名称：

  DOTA-tris(OPp ester) as a bifunctional prochelator for the preparation of DOTA–peptide conjugates

  摘要：

  Peptides containing the chelator DOTA have gained importance for molecular imaging and therapy with radionuclides. However, all synthons described for the convergent solid phase synthesis of DOTA-peptide conjugates show windows of stability that are too narrow to allow a clean and convergent deprotection process. The synthesis of the new prochelator DOTA-tris(OPp ester) starting from cyclen is reported. Using this prochelator for the synthesis of several DOTA peptide conjugates revealed that its cleavage-in contrast to the cleavage of DOTA-tris(tBu ester) conjugates-does not require an extended deprotection time, and therefore results in clean and homogenous products. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2012.10.007
• 作为产物：
  描述：

  溴乙酸叔丁酯 、 (1,4,7,10-四氮杂-环十二-1-基)-烯丙基乙酸酯 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以93%的产率得到tri-tert-butyl 2,2',2''-(10-(2-(allyloxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
  参考文献：
  名称：

  DOTA-tris(OPp ester) as a bifunctional prochelator for the preparation of DOTA–peptide conjugates

  摘要：

  Peptides containing the chelator DOTA have gained importance for molecular imaging and therapy with radionuclides. However, all synthons described for the convergent solid phase synthesis of DOTA-peptide conjugates show windows of stability that are too narrow to allow a clean and convergent deprotection process. The synthesis of the new prochelator DOTA-tris(OPp ester) starting from cyclen is reported. Using this prochelator for the synthesis of several DOTA peptide conjugates revealed that its cleavage-in contrast to the cleavage of DOTA-tris(tBu ester) conjugates-does not require an extended deprotection time, and therefore results in clean and homogenous products. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2012.10.007